Built For Commercial-Stage Biotech Value Creation
Our Investment Thesis
Valerium has designed an investment vehicle structured to own biotechnology companies through the multi-year period when commercialization, pipeline expansion, and platform development can meaningfully reshape value.
An Investment Structure for Long-Duration Ownership
o1
Commit Capital
Capital is committed in advance but remains uncalled until Valerium identifies a high-conviction opportunity.
o2
Open a Sleeve
A dedicated investment sleeve opens only when Valerium is ready to invest.
o3
Own Through the Value Creation Cycle
Each sleeve is designed for long-duration ownership through commercialization, pipeline expansion, and platform development.
o4
Return Capital
Investors may receive returns in cash or in-kind stock, depending on the investment outcome and election.
Commercial Stage or De-Risked Phase 3
Clinical development risk has been eliminated. These companies have demonstrated commercial viability, or are close enough that the risk-reward is asymmetric.
what we’re looking for
Undervalued Pipeline and Platform
Lead assets can demonstrate the viability of a company’s platform technology, presaging multiple future pipeline and commercialization opportunities that may still be underappreciated by the market.
$1B–$10B Market Cap
Large enough to have infrastructure and credibility. Small enough that the full value story is not yet reflected in the price.
Large-Cap Potential
These companies have the potential to scale into durable, standalone biotech platforms over time.
Investment Opportunities
For investment inquiries or access to private investor materials, please contact us directly.